CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike

Rhea-AI Filing Summary

CytomX Therapeutics director Halley E. Gilbert received a new stock option grant for 59,000 shares of common stock at an exercise price of $2.96 per share. This is a compensation-related award, not an open-market purchase or sale.

The option vests in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that date. Following this grant, Gilbert is reported as holding 59,000 stock options directly.

Insights

Equity Compensation Analyst

Routine director stock option grant with time-based vesting.

Director Halley E. Gilbert received a stock option covering 59,000 shares of CytomX Therapeutics common stock at an exercise price of $2.96 per share. The Form 4 characterizes this as a grant or award, typical for board compensation rather than a market trade.

The footnote states that 100% of the option will vest on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, contingent on continued board service. This time-based vesting aligns the director’s incentives with longer-term company performance.

There are no sales or exercises reported, and 59,000 options are shown as the total held after the transaction. As a standard equity award without accompanying disposals, this event is generally viewed as administrative and does not materially alter the investment thesis.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gilbert Halley E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	59,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 59,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 59,000 shares Exercise price: $2.96 per share Post-grant option holdings: 59,000 options +2 more

5 metrics

Option grant size 59,000 shares Stock Option (Right to Buy) granted to director

Exercise price $2.96 per share Conversion or exercise price of stock option

Post-grant option holdings 59,000 options Total derivative shares following transaction

Vesting condition 100% time-based Vests by first anniversary or 2027 annual meeting with continued service

Expiration date June 16, 2036 Option expiration date for the granted award

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 2.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service as a director regulatory

"assuming continuous service as a director until such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:49 PM Accepted by SEC EDGAR 06/22/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilbert Halley E

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/17/2026		A		59,000		(1)	06/16/2036	Common Stock	59,000	$0	59,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Halley E. Gilbert	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CytomX Therapeutics (CTMX) director Halley E. Gilbert report on this Form 4?

Halley E. Gilbert reported receiving a stock option grant for 59,000 shares of CytomX Therapeutics common stock. The option has an exercise price of $2.96 per share and is classified as a grant or award, not an open-market transaction.

How many CytomX Therapeutics (CTMX) options did Halley E. Gilbert receive and at what price?

Halley E. Gilbert was granted options covering 59,000 shares of CytomX Therapeutics common stock at an exercise price of $2.96 per share. These options provide the right to buy shares at that fixed price once vested, subject to continued board service.

When do Halley E. Gilbert’s CytomX (CTMX) stock options vest?

Gilbert’s options vest 100% on the earlier of the first anniversary of the grant date or the 2027 annual meeting of CytomX stockholders. Vesting requires continuous service as a director through that vesting date, according to the footnote disclosure.

Is the CytomX (CTMX) Form 4 for Halley E. Gilbert a stock purchase or a compensation grant?

The Form 4 reflects a compensation-related stock option grant, not a market purchase. The transaction code is “A” for grant or award, with 59,000 options given at a $2.96 exercise price and no cash stock purchase reported in the filing.

How many CytomX (CTMX) options does Halley E. Gilbert hold after this reported grant?

After the reported transaction, Gilbert holds 59,000 stock options directly, as shown in the post-transaction holdings field. This total corresponds to the newly granted options and no additional derivative holdings are listed in this Form 4 excerpt.